DRUG DEVELOPMENT IN CHINA – Moving Beyond the Me-Too Path

We have to thank Liu and colleagues for a thorough review of pharmaceutical development activities in China and elsewhere during the last decade.[1]  The authors reviewed a total of 34,844 Phase 1-3 trials, showing a significant uptick in studies initiated by Chinese companies.  Compared to 2015, trial numbers have steadily Continue reading DRUG DEVELOPMENT IN CHINA – Moving Beyond the Me-Too Path

NANOBODIES FOR AUTOIMMUNE DISEASES

Thrombotic thrombocytopenic purpura (TTP) is a devastating disease with a downhill course of neurologic, renal and cardiac complications leading to death at a young age if untreated.  Thrombocytopenia and thrombosis are its hallmark, with fever, anemia and neurologic deficits. It is caused by large aggregates of vWF, a protein which Continue reading NANOBODIES FOR AUTOIMMUNE DISEASES